-
公开(公告)号：US20140294807A1
公开(公告)日：2014-10-02
申请号：US14067799
申请日：2013-10-30
申请人： ROCHE GLYCART AG
发明人： THOMAS FRIESS , CHRISTIAN KLEIN , PABLO UMANA
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K2039/507 , C07K16/2887 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/56
摘要： The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的I型抗CD20抗体和II型抗-CD20抗体的组合疗法。 本发明的一个方面是包含I型抗CD20抗体和II型抗-CD20抗体的组合物。 本发明的另一方面是包含I型抗CD20抗体和II型抗CD20抗体的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同给予I型抗CD20抗体和II型抗-CD20抗体。
-
公开(公告)号：US20140242083A1
公开(公告)日：2014-08-28
申请号：US14187507
申请日：2014-02-24
申请人： ROCHE GLYCART AG
发明人： Thomas Hofer , Ralf Hosse , Ekkehard Moessner
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/3053 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/92
摘要： The invention provides anti-MCSP antibodies and methods of using the same.
摘要翻译： 本发明提供抗MCSP抗体及其使用方法。
-
53.发明申请公开(公告)号：US20140242079A1
公开(公告)日：2014-08-28
申请号：US14188486
申请日：2014-02-24
申请人： ROCHE GLYCART AG
发明人： Marina Bacac , Thomas Hofer , Ralf Hosse , Christiane Jaeger , Christian Klein , Ekkehard Moessner , Pablo Umana , Tina Weinzierl
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , A61K2039/505 , C07K16/3007 , C07K16/3053 , C07K2317/31 , C07K2317/33 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/64 , C07K2317/66 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
摘要翻译： 本发明一般涉及用于T细胞活化和对特异性靶细胞的重新定向的新型双特异性抗原结合分子。 此外，本发明涉及编码这种双特异性抗原结合分子的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及用于产生本发明的双特异性抗原结合分子的方法以及在治疗疾病中使用这些双特异性抗原结合分子的方法。
-
54.发明申请Predictive biomarker for cancer treatment with ADCC-enhanced antibodies 审中-公开用ADCC增强抗体进行癌症治疗的预测性生物标志物公开(公告)号：US20140227256A1
公开(公告)日：2014-08-14
申请号：US14159895
申请日：2014-01-21
申请人： Roche Glycart AG
发明人： Lilla Di Scala , Stefan Evers , Christian Gerdes , Christoph Mancao , Alexandre Passioukov , Pablo Umana
IPC分类号： G01N33/574 , C07K16/30
CPC分类号： G01N33/57492 , C07K16/30 , G01N33/574 , G01N2333/7051 , G01N2333/70535 , G01N2800/52
摘要： The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
摘要翻译： 本发明涉及用于鉴定被诊断患有癌症的患者将最受益于通过包含ADCC增强抗体的抗癌疗法治疗最有益的方法。
-
55.发明申请Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof 有权绑定EGFR的抗原结合分子，编码相同的载体及其用途公开(公告)号：US20140227253A1
公开(公告)日：2014-08-14
申请号：US14084303
申请日：2013-11-19
申请人： Roche GlycArt AG
发明人： Pablo UMAÑA , Ekkehard MÖSSNER
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K38/179 , A61K45/06 , A61K47/6803 , A61K47/6817 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2319/00
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
摘要翻译： 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人EGFR特异的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
公开(公告)号：US20140065097A1
公开(公告)日：2014-03-06
申请号：US13971757
申请日：2013-08-20
申请人： Roche Glycart AG
CPC分类号： C07K16/32 , A61K38/00 , A61K38/2013 , A61K45/06 , A61K47/6813 , C07K14/52 , C07K19/00 , C07K2319/33 , A61K2300/00
摘要： The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
摘要翻译： 本发明提供了（a）包含至少一个抗原结合部分和效应部分的免疫偶联物的组合，和（b）工程改造成具有增强的效应子功能的抗体，用于治疗有需要的个体中的疾病。 还提供了包含组合的药物组合物和使用它们的方法。
-
57.发明申请COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE 审中-公开含有FLUDARABINE和/或MITOXANTRONE的胶原蛋白CD20抗体的组合治疗公开(公告)号：US20140010804A1
公开(公告)日：2014-01-09
申请号：US13745652
申请日：2013-01-18
申请人： Roche Glycart AG
IPC分类号： A61K39/395 , A61K31/137 , A61K31/675 , A61K31/7076
CPC分类号： C07K16/2887 , A61K31/136 , A61K31/137 , A61K31/661 , A61K31/675 , A61K31/7076 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/73 , A61K2300/00
摘要： The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
摘要翻译： 本发明涉及非糖基化抗CD20抗体与氟达拉滨和/或米托蒽醌治疗癌症的联合治疗，特别是与含有氟达拉滨和/或非氟沙星的非糖基化人源化B-Ly1抗体的CD20表达癌症的组合疗法 米托蒽醌。
-
公开(公告)号：US08394928B2
公开(公告)日：2013-03-12
申请号：US12868845
申请日：2010-08-26
申请人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
发明人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
IPC分类号： C12P21/08
CPC分类号： C07K16/30 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对人CDCP1（抗CDCP1抗体）的人源化抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
59.发明申请Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier 审中-公开血脑屏障pH依赖通道的方法和结构公开(公告)号：US20120282176A1
公开(公告)日：2012-11-08
申请号：US13450240
申请日：2012-04-18
申请人： Bernd Bohrmann , Per-Ola Freskgard , Adrian Hugenmatter , Erhard Kopetzki , Ekkehard Moessner , Jens Niewoehner , Hadassah Sumum Sade , Pablo Umaña
发明人： Bernd Bohrmann , Per-Ola Freskgard , Adrian Hugenmatter , Erhard Kopetzki , Ekkehard Moessner , Jens Niewoehner , Hadassah Sumum Sade , Pablo Umaña
IPC分类号： A61K39/395 , G01N33/53 , A61K51/10 , A61K9/127 , A61P25/00 , C07K19/00 , C12N9/96 , B82Y5/00
CPC分类号： C07K16/2881 , A61K2039/54 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
摘要翻译： 本文报道了融合多肽，其包含i）至少一个结合位点， 其包含抗体重链可变结构域和抗体轻链可变结构域，并结合内化细胞表面受体，和ii）至少一种药学活性化合物，其中结合对的EC 50值与内化 在pH5.5下测定的细胞表面受体高于在pH7.4下测定的相同结合对的EC50值，以及用于在血脑屏障上递送药物活性化合物的用途。
-
公开(公告)号：US20120251529A1
公开(公告)日：2012-10-04
申请号：US13408171
申请日：2012-02-29
申请人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
发明人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
CPC分类号： C07K16/42 , A61K39/39566 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K16/3007 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
摘要翻译： 本发明提供了结合膜结合CEA的抗原结合分子（ABM），其包括具有改善的治疗性质的ABM及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
176 条记录 (耗时 0.035 秒)
